United Therapeutics Share Price (NASDAQ: UTHR)

$312.92

▲

0.86

(0.28%)

Last updated on August 16, 2025 at 1:29 AM IST

$₹

Check the interactive United Therapeutics Stock chart to analyse performance

United Therapeutics stock performance

as on August 16, 2025 at 1:29 AM IST

Today's Low:$311.06
Today's High:$313.20
$312.92
0.59%
Downside
Day's Volatility :0.68%
Upside
0.09%
52 Weeks Low:$266.98
52 Weeks High:$417.82
$312.92
14.68%
Downside
52 Weeks Volatility :36.1%
Upside
25.11%

United Therapeutics Stock Returns

Period	United Therapeutics Corporation	Sector (Health Care)	Index (Russel 2000)
3 Months	2.58%	2.3%	0.0%
6 Months	-15.99%	-5.9%	0.0%
1 Year	-2.43%	-10.9%	0.0%
3 Years	41.32%	1.7%	-12.4%

United Therapeutics Corporation Key Stats

Check United Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$312.06
Open	$312.385
Today's High	$313.2
Today's Low	$311.06
Market Capitalization	$14.2B
Today's Volume	$703.8K
52 Week High	$417.815
52 Week Low	$266.98
Revenue TTM	$3.1B
EBITDA	$1.6B
Earnings Per Share (EPS)	$25.62
PE Ratio	12.22
Profit Margin	40.36%
Quarterly Earnings Growth YOY	0.1%
Return On Equity TTM	19.3%

Stock Returns calculator for United Therapeutics Stock including INR - Dollar returns

The United Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

United Therapeutics investment value today

Current value as on today

₹93,980

Returns

₹6,020

(-6.02%)

Returns from United Therapeutics Stock

₹10,230 (-10.23%)

Dollar Returns*

₹4,210 (+4.21%)

Indian investors sentiment towards United Therapeutics Stock

27%

Period: Jul 17, 2025 to Aug 16, 2025. Change in 30 Days versus previous period

Search interest for United Therapeutics Stock from India on INDmoney has increased by 27% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in United Therapeutics Corporation

Name
Holdings %
Name
Holdings %
BlackRock Inc
12.04%
Vanguard Group Inc
9.86%
venBio Select Advisor LLC
5.91%
State Street Corp
4.93%
Renaissance Technologies Corp
4.66%
Wellington Management Company LLP
4.48%

Analyst Recommendation on United Therapeutics Stock

Rating

Trend

Buy

81%Buy

13%Hold

4%Sell

Based on 22 Wall street analysts offering stock ratings for United Therapeutics(by analysts ranked 0 to 5 stars)

United Therapeutics Share Price Target

What analysts predicted

Upside of 21.22%

Target:

$379.32

Current:

$312.92

United Therapeutics share price target is $379.32, a slight Upside of 21.22% compared to current price of $312.92 as per analysts' prediction.

United Therapeutics Stock Insights

Price Movement
In the last 7 days, UTHR stock has moved up by 3.9%
Increasing Revenue
Revenue is up for the last 3 quarters, 735.9M → 798.6M (in $), with an average increase of 3.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 322.2M → 309.5M (in $), with an average decrease of 3.9% per quarter
UTHR vs HLN (1 yr)
In the last 1 year, United Therapeutics Corporation has experienced a drawdown of -2.4%, however Haleon Plc Spon Ads resisted the overall trend and outperformed by 2.0%
UTHR vs HLN (3 yr)
In the last 3 years, Haleon Plc Spon Ads has given 51.9% return, outperforming this stock by 10.6%
Price to Sales
ForUTHR every $1 of sales, investors are willing to pay $4.6, whereas for Haleon Plc Spon Ads, the investors are paying $4.0 for every $1 of sales.

United Therapeutics Corporation Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$1.4B	↓ 11.0%
Net Income	$-104.5M	↓ 117.74%
Net Profit Margin	-7.21%	↓ 43.41%

	FY20	Y/Y Change
Revenue	$1.5B	↑ 2.38%
Net Income	$514.8M	↓ 592.63%
Net Profit Margin	34.71%	↑ 41.92%

	FY21	Y/Y Change
Revenue	$1.7B	↑ 13.63%
Net Income	$475.8M	↓ 7.58%
Net Profit Margin	28.23%	↓ 6.48%

	FY22	Y/Y Change
Revenue	$1.9B	↑ 14.88%
Net Income	$727.3M	↑ 52.86%
Net Profit Margin	37.56%	↑ 9.33%

	FY23	Y/Y Change
Revenue	$2.3B	↑ 20.2%
Net Income	$984.8M	↑ 35.4%
Net Profit Margin	42.31%	↑ 4.75%

	FY24	Y/Y Change
Revenue	$2.9B	↑ 23.63%
Net Income	$1.2B	↑ 21.35%
Net Profit Margin	41.53%	↓ 0.78%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$677.7M	↑ 10.25%
Net Income	$306.6M	↑ 41.23%
Net Profit Margin	45.24%	↑ 9.92%

	Q2 FY24	Q/Q Change
Revenue	$714.9M	↑ 5.49%
Net Income	$278.1M	↓ 9.3%
Net Profit Margin	38.9%	↓ 6.34%

	Q3 FY24	Q/Q Change
Revenue	$748.9M	↑ 4.76%
Net Income	$309.1M	↑ 11.15%
Net Profit Margin	41.27%	↑ 2.37%

	Q4 FY24	Q/Q Change
Revenue	$735.9M	↓ 1.74%
Net Income	$301.3M	↓ 2.52%
Net Profit Margin	40.94%	↓ 0.33%

	Q1 FY25	Q/Q Change
Revenue	$794.4M	↑ 7.95%
Net Income	$322.2M	↑ 6.94%
Net Profit Margin	40.56%	↓ 0.38%

	Q2 FY25	Q/Q Change
Revenue	$798.6M	↑ 0.53%
Net Income	$309.5M	↓ 3.94%
Net Profit Margin	38.76%	↓ 1.8%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$1.3B	↓ 6.85%

	FY20	Y/Y Change
Profit	$1.4B	↑ 3.31%

	FY21	Y/Y Change
Profit	$1.6B	↑ 13.66%

	FY22	Y/Y Change
Profit	$1.8B	↑ 14.5%

	FY23	Y/Y Change
Profit	$2.1B	↑ 15.67%

	FY24	Y/Y Change
Profit	$2.6B	↑ 24.04%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$604.8M	↑ 11.24%

	Q2 FY24	Q/Q Change
Profit	$637.1M	↑ 5.34%

	Q3 FY24	Q/Q Change
Profit	$665.8M	↑ 4.5%

	Q4 FY24	Q/Q Change
Profit	$660.0M	↓ 0.87%

	Q1 FY25	Q/Q Change
Profit	$701.9M	↑ 6.35%

	Q2 FY25	Q/Q Change
Profit	$711.0M	↑ 1.3%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-206.6M	↓ 126.54%
Investing Cash Flow	$-335.4M	↓ 59.13%
Financing Cash Flow	$611.2M	↑ 9601.59%

	FY20	Y/Y Change
Operating Cash Flow	$755.7M	↓ 465.78%
Investing Cash Flow	$-738.5M	↑ 120.18%
Financing Cash Flow	$-16.9M	↓ 102.77%

	FY21	Y/Y Change
Operating Cash Flow	$598.2M	↓ 20.84%
Investing Cash Flow	$-486.9M	↓ 34.07%
Financing Cash Flow	$44.8M	↓ 365.09%

	FY22	Y/Y Change
Operating Cash Flow	$802.5M	↑ 34.15%
Investing Cash Flow	$-811.5M	↑ 66.67%
Financing Cash Flow	$75.4M	↑ 68.3%

	FY23	Y/Y Change
Operating Cash Flow	$978.0M	↑ 21.87%
Investing Cash Flow	$-719.6M	↓ 11.32%
Financing Cash Flow	$-11.9M	↓ 115.78%

	FY24	Y/Y Change
Operating Cash Flow	$1.3B	↑ 35.7%
Investing Cash Flow	$417.2M	↓ 157.98%
Financing Cash Flow	$-1.3B	↑ 10444.54%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$376.5M	↑ 149.83%
Investing Cash Flow	$735.3M	↑ 1646.56%
Financing Cash Flow	$-1.1B	↑ 1050.86%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$232.2M	↓ 38.33%
Investing Cash Flow	$-80.0M	↓ 110.88%
Financing Cash Flow	$-48.0M	↓ 95.51%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$377.2M	↑ 62.45%
Investing Cash Flow	$-114.9M	↑ 43.63%
Financing Cash Flow	$-64.1M	↑ 33.54%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$341.2M	↓ 9.54%
Investing Cash Flow	$-123.2M	↑ 7.22%
Financing Cash Flow	$-74.7M	↑ 16.54%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$461.2M	↑ 35.17%
Investing Cash Flow	$-164.7M	↑ 33.69%
Financing Cash Flow	$-93.8M	↑ 25.57%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$191.7M	↓ 58.43%
Investing Cash Flow	$-299.9M	↑ 82.09%
Financing Cash Flow	$-198.6M	↑ 111.73%

United Therapeutics Technicals Summary

Sell

Neutral

Buy

United Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

United Therapeutics Corporation Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
United Therapeutics Corporation	5.34%	-15.99%	-2.43%	41.32%	76.13%
Haleon Plc Spon Ads	0.57%	-3.45%	-0.36%	57.6%	30.16%
Zoetis Inc.	2.72%	-1.51%	-16.11%	-10.64%	-2.1%
Neurocrine Biosciences Inc.	-0.95%	16.56%	-8.39%	26.59%	13.86%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
United Therapeutics Corporation	12.22	12.22	1.43	26.95	0.19	0.13	NA	158.65
Haleon Plc Spon Ads	21.56	21.56	3.11	0.49	0.09	0.05	0.01	1.77
Zoetis Inc.	26.24	26.24	2.42	6.32	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	38.85	38.85	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
United Therapeutics Corporation	Buy	$14.2B	76.13%	12.22	40.36%
Haleon Plc Spon Ads	Buy	$43.5B	30.16%	21.56	13.81%
Zoetis Inc.	Buy	$67.6B	-2.1%	26.24	27.83%
Neurocrine Biosciences Inc.	Buy	$13.0B	13.86%	38.85	13.88%

About United Therapeutics Corporation

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Organization	United Therapeutics
Employees	1305
CEO	Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Industry	Health Technology

Key Management of United Therapeutics Corporation

Name	Title
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.	Founder, Chairman & CEO
Mr. Michael I. Benkowitz	President & COO
Mr. James C. Edgemond	CFO & Treasurer
Mr. Paul A. Mahon J.D.	Executive VP, General Counsel & Corporate Secretary
Mr. Dewey Steadman C.F.A.	Head of Investor Relations
Ms. Holly Hobson	Associate Vice President of Human Resources
Kevin T. Gray	Senior Vice President of Strategic Operations & Logistics
Mr. Patrick Poisson	Executive VP of Technical Operations
Dr. Leigh Peterson	Executive Vice President of Product Development & Xenotransplantation
Mr. Gil Golden	Senior VP & Chief Medical Officer

Important FAQs about investing in UTHR Stock from India :

What is United Therapeutics share price today?

United Therapeutics share price today is $312.92 as on August 16, 2025 at 1:29 AM IST at the close of the market. United Therapeutics share today touched a day high of $313.20 and a low of $311.06.

What is the 52 week high and 52 week low for United Therapeutics share?

United Therapeutics share touched a 52 week high of $417.82 and a 52 week low of $266.98. United Therapeutics stock price today, August 16, 2025 at 1:29 AM IST is trending at $312.92, lower by 25.11% versus the 52 week high.

How to invest in United Therapeutics Stock (UTHR) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for United Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in United Therapeutics Shares that will get you 0.0048 shares as per United Therapeutics share price of $312.92 per share as on August 16, 2025 at 1:29 AM IST.

What is the minimum amount required to buy United Therapeutics Stock (UTHR) from India?

Indian investors can start investing in United Therapeutics (UTHR) shares with as little as ₹87.492 or $1 (as of August 17, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹874.92 in United Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 17, 2025). Based on United Therapeutics share’s latest price of $312.92 as on August 16, 2025 at 1:29 AM IST, you will get 0.0320 shares of United Therapeutics. Learn more about fractional shares .

What are the returns that United Therapeutics has given to Indian investors in the last 5 years?

United Therapeutics stock has given 76.13% share price returns and 17.06% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?